Description du projet
Spectroscopie Raman améliorée par la surface pour l’antibiothérapie des patients atteints de sepsis
Le sepsis constitue une importante une cause de décès en hôpital en Europe. Dans environ 50 % des cas de sepsis, le dosage des antibiotiques est inapproprié, ce qui dégrade les résultats cliniques en raison de l’augmentation des effets indésirables, de la toxicité et de la résistance aux antibiotiques. Le suivi thérapeutique pharmacologique (STP) devrait considérablement améliorer le dosage des antibiotiques, mais les procédures actuelles sont entravées par leur lenteur, leur coût et leur manque d’adaptabilité. Le projet ACU-SERS financé par le CEI propose un système entièrement automatisé pour le prétraitement des échantillons biologiques, la séparation des analytes et l’analyse, qui peut fournir un niveau quantitatif de médicament antibiotique en seulement 15 minutes. Ce système intègre la microfluidique centrifuge et la technologie des puces de spectroscopie Raman améliorée par la surface (SERS), dans un dispositif de paillasse convivial. Le projet entend valider l’évolutivité et le potentiel commercial, et effectuer le travail préparatoire au lancement d’une entreprise spin-off.
Objectif
Sepsis is a leading cause of death in hospitals resulting in ~700k deaths in Europe each year. Patients urgently require critical care and are admitted to an intensive care unit (ICU), where they are treated with antibiotics. However, antibiotic dosing is inappropriate in ~50% of sepsis patients, causing poor clinical outcomes due to increased adverse events, (neuro)toxicity and contributing to antibiotic resistance. Antibiotic dosing can be significantly improved through therapeutic drug monitoring (TDM), but current workflows for drug quantification in clinics and ICU are slow, expensive, and inflexible, which have greatly limited TDM implementation. We develop ACU-SERS: a first-in-class, highly flexible, fast, and cost-effective system that fully automates the biological sample pre-treatment, analyte separation and analysis and provides a quantitative antibiotic drug level concentration in ~15 minutes. ACU-SERS' breakthrough technology combines centrifugal microfluidics with an integrated surface-enhanced Raman spectroscopy (SERS) chip to perform label-free, rapid detection and quantification in an easy-to-use benchtop device. Based on the H2020 SERSing project, this project builds on developing the Raman-based analyser device and the optimal cartridge, as well as validating the scalability of the product and the system with clinical samples. From the commercial side, we will validate the commercial potential of our solution, found a spin-off company to commercialize the technology, and make it investment-ready. We envision that the spin-off will generate early revenues from direct sales in our initial target markets within the EU. After demonstrating market traction, we will seek to close a global distribution deal with a large diagnostics company for the TDM antibiotic market. Revenues will be reinvested to adapt ACU-SERS for TDM applications in other potential markets, such as antiepileptics, immunosuppressants and applications in pharmaceutical research.
Champ scientifique
- natural sciencesphysical sciencesclassical mechanicsfluid mechanicsmicrofluidics
- medical and health sciencesclinical medicinecritical care medicine
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
- natural sciencesphysical sciencesopticsspectroscopy
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Régime de financement
HORIZON-EIC - HORIZON EIC GrantsCoordinateur
2800 Kongens Lyngby
Danemark